Top Markets
#1 Black Phoenix Black Phoenix +829.59%
#2 pipedog pipedog +41.28%
#3 PondCoin PondCoin +35.42%
#4 Bless Bless +35.40%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.00%
#7 Beam Beam +24.62%
#8 Seeker Seeker +21.01%
#9 Magma Finance Magma Finance +20.64%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Clasificación en acciones #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Precio por acción
$64.97
Última sincronización: 2024-05-20
Capitalización bursátil
$1.97B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Alpine Immune Sciences, Inc. (ALPN)

Categoría

Healthcare
Ingresos de Alpine Immune Sciences, Inc. (ALPN)
Ingresos en Mar 2024 TTM: $56.52M
Según los últimos informes financieros de Alpine Immune Sciences, Inc., los ingresos actuales de la empresa (TTM) son $56.52M. En 2022, la empresa obtuvo unos ingresos de $30.06M un aumento con respecto a los ingresos del año 2021, que fueron de $23.44M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Alpine Immune Sciences, Inc. desde 2012 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 22,235.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 10,553.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 27,755.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 3,841.90%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH